Summit Therapeutics Inc. (NASDAQ:SMMT) on Thursday reported an adjusted loss of 19 cents, better than the consensus loss of 28 cents per share.
Aggregate cash and cash equivalents and short-term investments were $690.7 million.
Company Raises Capital But Says More Funding Will Be Needed
During the second quarter of 2026, the company raised $230.8 million in gross proceeds through its ATM facility. Subsequent to June 2026, the company raised an additional $68.4 million in gross proceeds through its ATM facility.
In its SEC quarterly filing, the cancer drug developer reported that it has an accumulated deficit of $2,699.3 million, and expects to continue to generate operating losses for the foreseeable future.
Cash and cash equivalents and short-term investments are not sufficient to fund the company’s planned operations for a period of at least one year.
Going Concern Warning Highlights Future Cash Requirements
Summit said it continues to evaluate options to finance operating cash needs for product candidates further.
The company said that if it is unable to obtain funding when required in the future, it could be required to delay or reduce research and development programs, product portfolio expansion, or future commercialization efforts.
These conditions raise substantial doubt about the ability to continue as a going concern.
Ridinilazole Sale Adds Potential Payments
Earlier in July, Summit Therapeutics agreed to sell ridinilazole, an investigational Phase 3 precision antibiotic, to Toronto-based Biossil, Inc.
Summit will receive $500,000 upfront and up to $104.5 million in regulatory and commercial milestones, plus tiered royalties on net sales.
SMMT Price Action: Summit Therapeutics shares were down 6.78% at $13.96 at the time of publication on Friday, according to Benzinga Pro data.
Photo by Piotr Swat via Shutterstock
